{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T22:35:38Z","timestamp":1769553338015,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.urolonc.2024.04.020","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T13:44:00Z","timestamp":1714571040000},"page":"333.e1-333.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pathologic and survival outcomes following radical cystectomy for \u201cprogressive\u201d and \u201cde novo\u201d muscle-invasive bladder cancer: A meta-analysis stratified by neoadjuvant chemotherapy status"],"prefix":"10.1016","volume":"42","author":[{"given":"Leilei","family":"Xia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anosh","family":"Dadabhoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika L.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sejal V.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel S.","family":"Roberson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Guzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siamak","family":"Daneshmand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.urolonc.2024.04.020_bib0001","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.04.020_bib0002","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.urolonc.2024.04.020_bib0003","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2024.04.020_bib0004","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.urolonc.2024.04.020_bib0005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.eururo.2014.09.007","article-title":"Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"67","author":"Zargar","year":"2015","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.04.020_bib0006","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","article-title":"Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis","volume":"65","author":"Petrelli","year":"2014","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.04.020_bib0007","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.eururo.2017.05.016","article-title":"Oncologic outcomes for patients with residual cancer at cystectomy following neoadjuvant chemotherapy: a pathologic stage-matched analysis","volume":"72","author":"Bhindi","year":"2017","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2024.04.020_bib0008","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/j.1464-410X.2009.08626.x","article-title":"Outcome after radical cystectomy in patients with clinical T2 bladder cancer in whom neoadjuvant chemotherapy has failed","volume":"104","author":"Manoharan","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2024.04.020_bib0009","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.euros.2022.05.001","article-title":"The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy","volume":"41","author":"D'Andrea","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2024.04.020_bib0010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.urology.2022.06.012","article-title":"Comparing pathologic and survival outcomes between primary and secondary muscle invasive bladder cancer when treated by radical cystectomy with or without neoadjuvant chemotherapy","volume":"168","author":"Benidir","year":"2022","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.urolonc.2024.04.020_bib0011","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/JU.0000000000001715","article-title":"No outcome differences after cystectomy between patients with de novo muscle-invasive bladder cancer compared to progressors: a retrospective population-based study","volume":"206","author":"Lusty","year":"2021","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.04.020_bib0012","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/JU.0000000000001943","article-title":"Progression of disease after bacillus calmette-guerin therapy: refining patient selection for neoadjuvant chemotherapy before radical cystectomy","volume":"206","author":"Hensley","year":"2021","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.04.020_bib0013","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","article-title":"Genomic differences between \"primary\" and \"secondary\" muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy","volume":"75","author":"Pietzak","year":"2019","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.04.020_bib0014","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/21681805.2022.2056633","article-title":"Primary versus secondary muscle-invasive bladder cancer: survival after curative treatment","volume":"56","author":"Moller","year":"2022","journal-title":"Scand J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.04.020_bib0015","doi-asserted-by":"crossref","first-page":"195.e191","DOI":"10.1016\/j.urolonc.2020.09.006","article-title":"Comparison of the prognosis of primary vs. progressive muscle invasive bladder cancer after radical cystectomy: results from a large multicenter study","volume":"39","author":"Nouhaud","year":"2021","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.04.020_bib0016","doi-asserted-by":"crossref","first-page":"e969","DOI":"10.1016\/j.clgc.2018.04.004","article-title":"History of non-muscle-invasive bladder cancer may have a worse prognostic impact in cT2-4aN0M0 bladder cancer patients treated with radical cystectomy","volume":"16","author":"Kayama","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2024.04.020_bib0017","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/bju.13146","article-title":"Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy","volume":"117","author":"Moschini","year":"2016","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.urolonc.2024.04.020_bib0018","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejso.2009.11.012","article-title":"Survival after cystectomy for invasive bladder cancer","volume":"36","author":"de Vries","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.urolonc.2024.04.020_bib0019","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.euros.2022.02.011","article-title":"Comparative outcomes of primary versus recurrent high-risk non-muscle-invasive and primary versus secondary muscle-invasive bladder cancer after radical cystectomy: results from a retrospective multicenter study","volume":"39","author":"Grossmann","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2024.04.020_bib0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2490-13-23","article-title":"The natural history of secondary muscle-invasive bladder cancer","volume":"13","author":"Hidas","year":"2013","journal-title":"BMC Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.04.020_bib0021","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.urology.2007.05.008","article-title":"Muscle-invasive bladder cancer: predictive factors and prognostic difference between primary and progressive tumors","volume":"70","author":"Turkolmez","year":"2007","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.urolonc.2024.04.020_bib0022","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.urology.2007.02.064","article-title":"Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion","volume":"69","author":"Lee","year":"2007","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.urolonc.2024.04.020_bib0023","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000075962","article-title":"Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation","volume":"72","author":"May","year":"2004","journal-title":"Urol Int"},{"issue":"4","key":"10.1016\/j.urolonc.2024.04.020_bib0024","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1046\/j.1464-4096.2001.001020.x","article-title":"Outcome of radical cystectomy for bladder cancer according to the disease type at presentation","volume":"89","author":"Yiou","year":"2002","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.urolonc.2024.04.020_bib0025","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7150\/ijms.49228","article-title":"Comparison of survival outcomes between primary and secondary muscle-invasive bladder cancer: an updated meta-analysis","volume":"18","author":"Zheng","year":"2021","journal-title":"Int J Med Sci"},{"issue":"10","key":"10.1016\/j.urolonc.2024.04.020_bib0026","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.3390\/cancers13102496","article-title":"Differential prognosis and response of denovo vs. secondary muscle-invasive bladder cancer: an updated systematic review and meta-analysis","volume":"13","author":"Pones","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.urolonc.2024.04.020_bib0027","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1038\/s41598-018-26002-6","article-title":"Oncological outcome of primary and secondary muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"8","author":"Ge","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2024.04.020_bib0028","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijsu.2018.02.049","article-title":"Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: A systematic review and meta-analysis","volume":"52","author":"Chen","year":"2018","journal-title":"Int J Surg"},{"key":"10.1016\/j.urolonc.2024.04.020_bib0029","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"24","key":"10.1016\/j.urolonc.2024.04.020_bib0030","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.urolonc.2024.04.020_bib0031","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.urolonc.2024.04.020_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002742","article-title":"COSMOS-E: guidance on conducting systematic reviews and meta-analyses of observational studies of etiology","volume":"16","author":"Dekkers","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.urolonc.2024.04.020_bib0033","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"7867","key":"10.1016\/j.urolonc.2024.04.020_bib0034","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924004381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924004381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T11:46:14Z","timestamp":1737632774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924004381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1078143924004381"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.04.020","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathologic and survival outcomes following radical cystectomy for \u201cprogressive\u201d and \u201cde novo\u201d muscle-invasive bladder cancer: A meta-analysis stratified by neoadjuvant chemotherapy status","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}